← Eichor
Study identifier: NCT07221474 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

Condition: Squamous Non-small Cell Lung Cancer  ·  Sponsor: Merck Sharp & Dohme LLC

PhasePhase 2
Planned participants180
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Researchers want to know if intismeran autogene (the study treatment) given with pembrolizumab and chemotherapy can treat metastatic treatment-naive squamous non-small cell lung cancer (NSCLC). Intismeran autogene is designed to help a person's immune system attack their specific cancer. The goal of this study is to learn if people who receive intismeran autogene with pembrolizumab and chemotherapy live longer overall and without the cancer growing or spreading compared to people who receive placebo with pembrolizumab and chemotherapy. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of the study treatment.

This description comes directly from the study's public registry record.

Talk to the study team

Toll Free Number  ·  1-888-577-8839  ·  Trialsites@msd.com

Always discuss trial participation with your own doctor first.

Locations (54)

Moffitt Cancer Center ( Site 0021)Tampa, Florida, United StatesRecruiting
Washington University School of Medicine ( Site 0024)St Louis, Missouri, United StatesRecruiting
Valley Health Systems - Ridgewood Campus ( Site 0010)Paramus, New Jersey, United StatesRecruiting
New York Oncology Hematology (NYOH) - Albany Medical Center ( Site 9001)Albany, New York, United StatesRecruiting
Cleveland Clinic - Ohio ( Site 0016)Cleveland, Ohio, United StatesRecruiting
Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0025)Corvallis, Oregon, United StatesRecruiting
Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 9000)Nashville, Tennessee, United StatesRecruiting
Texas Oncology - Central/South Texas ( Site 8002)Austin, Texas, United StatesRecruiting
Virginia Cancer Specialists ( Site 0003)Fairfax, Virginia, United StatesRecruiting
Swedish Medical Center-Swedish Cancer Institute ( Site 0023)Seattle, Washington, United StatesRecruiting
Hospital Italiano de Buenos Aires ( Site 0200)Ciudad Autonoma de Buenos Aires., Buenos Aires, ArgentinaRecruiting
Instituto Alexander Fleming ( Site 0201)Ciudad Autonoma de Buenos Aires, Buenos Aires, ArgentinaRecruiting

+ 42 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07221474